|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





* Vascular Biology Program and Department of Surgery, Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA;
Department of Radiation Oncology,
Department of Pediatric Oncology,
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; and
|| Clinic for Hepatobiliary Surgery and Visceral Transplantation, University Hospital Hamburg, Germany
1Correspondence: Vascular Biology Program, Children’s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA. E-mail: judah.folkman{at}childrens.harvard.edu
SPECIFIC AIMS
The aims of the study are: 1) to characterize an experimental model that recapitulates the clinical dormancy of nonangiogenic human tumors in mice; and 2) to study the physiological, cellular, and molecular mechanisms that underlie tumor dormancy that result from blocked angiogenesis.
PRINCIPAL FINDINGS
1. We show that while angiogenic liposarcomas expand rapidly after injection, dormant liposarcomas remain microscopic (Fig. 1
) up to one-third of the normal SCID mouse life span, although they contain a significant percentage of proliferating tumor cells
At a predictable time, these tumors complete the sequential steps to achieve the angiogenic phenotype, initiate growth, and expand in size. Once dormant tumors undergo the angiogenic switch and initiate growth and expansion of mass, the tumor growth kinetics are similar to those of the angiogenic fast-growing tumors.
|
2. This tumor growth pattern is similar both in subcutaneous (s.c.) and orthotopic environments
3. The growth and expansion of the tumor mass appears to be blocked because of impaired angiogenesis
This dormant phenotype is characterized by minimal or significantly reduced intratumoral microvessel density, which increases abruptly following the angiogenic switch (Fig. 2
) and leads to subsequent tumor growth. The scant microvessels that are observed in the microscopic dormant liposarcomas consist mainly of short clusters of endothelial cells that lack lumens.
|
4. Both tumor types cultured in vitro contain fully transformed cells, but only cells from the dormant human liposarcoma secrete relatively high levels of the angiogenesis inhibitors thrombospondin-1 and TIMP-1
5. This paper establishes the utility of using bioluminescence imaging to noninvasively monitor microscopic tumors over prolonged periods of time and to follow the kinetics of tumor dormancy and growth
CONCLUSIONS AND SIGNIFICANCE
The dormant human tumor, which contains fully transformed, proliferating neoplastic cells, is rendered harmless to the host by virtue of impaired angiogenesis (Fig. 3
). This strengthens the concept that microscopic nonangiogenic dormant tumors may be a potential target for nontoxic antiangiogenic prophylactic cancer therapy. The ability to detect and treat cancer while it is still microscopic in size and years before it is symptomatic, would potentially revolutionize the management of cancer patients. Therefore, this work provides a scientific rational for the treatment of cancer with nontoxic angiogenesis inhibitors guided by biomarkers, years before the tumor can be anatomically located and before it is symptomatic.
|
FOOTNOTES
To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.05-3946fje
This article has been cited by other articles:
![]() |
G. Lakka Klement, T.-T. Yip, F. Cassiola, L. Kikuchi, D. Cervi, V. Podust, J. E. Italiano, E. Wheatley, A. Abou-Slaybi, E. Bender, et al. Platelets actively sequester angiogenesis regulators Blood, March 19, 2009; 113(12): 2835 - 2842. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Almog, L. Ma, R. Raychowdhury, C. Schwager, R. Erber, S. Short, L. Hlatky, P. Vajkoczy, P. E. Huber, J. Folkman, et al. Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype Cancer Res., February 1, 2009; 69(3): 836 - 844. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ma and D. J. Waxman Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Cao and R. Langer A review of Judah Folkman's remarkable achievements in biomedicine PNAS, September 9, 2008; 105(36): 13203 - 13205. [Full Text] [PDF] |
||||
![]() |
C. M. Becker, N. Rohwer, T. Funakoshi, T. Cramer, W. Bernhardt, A. Birsner, J. Folkman, and R. J. D'Amato 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor-1{alpha} and Suppresses Growth of Lesions in a Mouse Model of Endometriosis Am. J. Pathol., February 1, 2008; 172(2): 534 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Cervi, T.-T. Yip, N. Bhattacharya, V. N. Podust, J. Peterson, A. Abou-Slaybi, G. N. Naumov, E. Bender, N. Almog, J. E. Italiano Jr, et al. Platelet-associated PF-4 as a biomarker of early tumor growth Blood, February 1, 2008; 111(3): 1201 - 1207. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Folkman Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin Sci. Signal., September 26, 2006; 2006(354): pe35 - pe35. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |